FBRX
Forte Biosciences, Inc. NASDAQ Listed Apr 13, 2017$26.09
Mkt Cap $362.3M
52w Low $6.19
67.2% of range
52w High $35.80
50d MA $28.33
200d MA $20.94
P/E (TTM)
-6.0x
EV/EBITDA
-55.8x
P/B
68.0x
Debt/Equity
0.0x
ROE
-113.8%
P/FCF
-78.7x
RSI (14)
—
ATR (14)
—
Beta
3.20
50d MA
$28.33
200d MA
$20.94
Avg Volume
284.6K
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
3060 Pegasus Park Drive · Dallas, TX 75247 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -1.42 | -1.45 | -2.1% | 25.90 | +4.9% | -4.0% | +2.9% | +3.4% | -1.0% | +0.4% | — |
| Nov 14, 2025 | AMC | -1.04 | -0.99 | +4.8% | 14.08 | -0.2% | +2.9% | +24.0% | +4.1% | +9.4% | -10.0% | — |
| Aug 14, 2025 | AMC | -1.21 | -0.96 | +20.7% | 10.82 | +1.6% | +6.9% | +2.9% | -1.3% | +0.1% | -5.5% | — |
| May 15, 2025 | AMC | -0.89 | -1.37 | -53.9% | 7.83 | +3.3% | +0.3% | -4.5% | +1.5% | -6.6% | +5.8% | — |
| Mar 24, 2025 | AMC | -4.55 | -2.45 | +46.2% | 6.32 | +10.9% | +34.7% | -3.6% | -3.5% | +3.7% | -5.4% | — |
| Nov 14, 2024 | AMC | -6.75 | -4.54 | +32.7% | 5.58 | +1.3% | +4.7% | +4.6% | -2.9% | +128.5% | +15.4% | — |
| Aug 14, 2024 | AMC | -4.00 | -6.75 | -68.8% | 9.75 | +0.0% | -20.5% | -3.2% | +10.0% | +0.0% | +0.4% | — |
| May 13, 2024 | AMC | -0.16 | -4.00 | -2400.0% | 17.75 | -2.8% | -4.2% | -5.9% | -1.6% | -4.6% | +1.0% | — |
| Mar 18, 2024 | AMC | -0.28 | -1.00 | -257.1% | 16.08 | +1.1% | +2.6% | +6.0% | -1.4% | +1.5% | +1.4% | — |
| Nov 13, 2023 | AMC | -14.25 | -6.50 | +54.4% | 10.77 | -4.8% | -9.5% | -2.6% | +3.3% | +14.5% | +8.5% | — |
| Aug 14, 2023 | AMC | — | -10.50 | — | 22.03 | -0.7% | -6.9% | +1.7% | +0.2% | -0.4% | -0.2% | — |
| May 15, 2023 | AMC | — | -8.00 | — | 27.03 | -0.1% | -2.9% | -1.9% | -4.3% | -0.2% | -0.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 17 | Chardan Capital | Maintains | Buy → Buy | — | $14.08 | $14.05 | -0.2% | +2.9% | +24.0% | +4.1% | +9.4% | -10.0% |
| Aug 15 | Chardan Capital | Maintains | Buy → Buy | — | $10.82 | $10.99 | +1.6% | +6.9% | +2.9% | -1.3% | +0.1% | -5.5% |
| Jun 24 | Chardan Capital | Maintains | Buy → Buy | — | $12.76 | $12.31 | -3.5% | +11.1% | -25.3% | +7.7% | +7.4% | +5.6% |
| Apr 1 | Chardan Capital | Maintains | Buy → Buy | — | $7.76 | $7.54 | -2.8% | -4.3% | -1.1% | -10.5% | -10.6% | -9.2% |
| Dec 4 | Chardan Capital | Maintains | Buy → Buy | — | $24.00 | $20.51 | -14.5% | -6.2% | +9.1% | +14.1% | -9.1% | -7.6% |
| Nov 15 | Chardan Capital | Maintains | Buy → Buy | — | $5.58 | $5.65 | +1.3% | +4.7% | +4.6% | -2.9% | +128.5% | +15.4% |
| Aug 19 | Chardan Capital | Maintains | Buy → Buy | — | $7.50 | $7.75 | +3.3% | +10.0% | +0.0% | +0.4% | -3.6% | -0.8% |
| Apr 8 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | $17.47 | $18.56 | +6.2% | +0.3% | +3.0% | +1.2% | -1.4% | +0.4% |
| Sep 20 | Chardan Capital | Upgrade | Sell → Neutral | — | $90.00 | $88.75 | -1.4% | -6.7% | +0.3% | -0.9% | +1.5% | -4.4% |
| Sep 3 | Truist | Downgrade | Buy → Hold | — | $714.75 | $141.25 | -80.2% | -82.3% | -17.2% | -1.0% | -2.7% | +1.7% |
| Sep 3 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $714.75 | $141.25 | -80.2% | -82.3% | -17.2% | -1.0% | -2.7% | +1.7% |
| Sep 3 | Chardan Capital | Downgrade | Buy → Sell | — | $714.75 | $141.25 | -80.2% | -82.3% | -17.2% | -1.0% | -2.7% | +1.7% |
| Sep 3 | Brookline Capital | Downgrade | Buy → Hold | — | $714.75 | $141.25 | -80.2% | -82.3% | -17.2% | -1.0% | -2.7% | +1.7% |
| Sep 3 | B. Riley Securities | Downgrade | Buy → Neutral | — | $714.75 | $141.25 | -80.2% | -82.3% | -17.2% | -1.0% | -2.7% | +1.7% |
| May 14 | B. Riley Securities | Maintains | Buy → Buy | — | $787.50 | $823.00 | +4.5% | +0.3% | +0.2% | +10.8% | +2.0% | +1.4% |
| Mar 26 | Citigroup | Maintains | Buy → Buy | — | $723.00 | $773.25 | +7.0% | +3.8% | +7.3% | -0.1% | +6.5% | -6.4% |
| Mar 17 | Chardan Capital | Maintains | Buy → Buy | — | $695.00 | $697.63 | +0.4% | -0.0% | -5.4% | +6.1% | +2.0% | -2.9% |
| Sep 24 | Chardan Capital | Maintains | Buy → Buy | — | $1163.00 | $1194.50 | +2.7% | -2.0% | +7.5% | +3.4% | -3.2% | -1.2% |
| Sep 10 | Chardan Capital | Maintains | Buy → Buy | — | $795.00 | $837.75 | +5.4% | +11.1% | +1.6% | +12.6% | +2.9% | +5.0% |
| Aug 28 | Chardan Capital | Upgrade | Neutral → Buy | — | $667.25 | $712.50 | +6.8% | +11.9% | +4.7% | -3.5% | -4.8% | -4.1% |
| Aug 28 | Brookline Capital | Maintains | Buy → Buy | — | $667.25 | $712.50 | +6.8% | +11.9% | +4.7% | -3.5% | -4.8% | -4.1% |
| Aug 25 | Truist | Maintains | Buy → Buy | — | $617.50 | $690.25 | +11.8% | +6.3% | +3.0% | -1.3% | +11.9% | +4.7% |
| Jun 22 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $357.75 | $380.75 | +6.4% | +2.2% | +6.6% | -6.6% | -4.5% | +6.5% |
No insider trades available.
8-K
Unknown — 8-K Filing
FBRX completed an underwritten offering with standard indemnification protections, meaning the company raised capital while underwriters assume liability risks, which typically signals growth ambitions but dilutes existing shareholders.
Apr 9
8-K
Unknown — 8-K Filing
Forte Biopharma's FB102 pipeline advancement and 2026 data readouts provide clinical validation catalysts that could drive significant stock appreciation if results prove positive, making near-term execution risk a key investment consideration.
Apr 1
Data updated apr 25, 2026 8:33am
· Source: massive.com